Phase I/II Study, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma
The purpose of this phase I/II study is to evaluate the safety and efficacy of Paclitaxel, Cisplatin, and Gemcitabine (GCN) in combination with Tumor Treatment Fields (TTF) in patients with metastatic or recurrent pancreatic cancer.
Study ID: MC210405
Trial Phase: Phase I/II
Trial Sponsor: Mayo Clinic, NovoCure Ltd.
Therapies Used in This Trial: Gemcitabine, Cisplatin, Paclitaxel